Newron Pharmaceuticals has announced the launch of its Phase III ENIGMA-TRS 2 trial in the US, marking an important step for the registrational programme for lead candidate evenamide in treatment-resistant schizophrenia (TRS). ENIGMA-TRS 2 is a global, randomised, double-blind, placebo-controlled,
08 Dec 2025
Newron Pharmaceuticals:Phase III ENIGMA-TRS 2 trial underway
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Newron Pharmaceuticals:Phase III ENIGMA-TRS 2 trial underway
Newron Pharmaceuticals S.p.A. (NWRN:SWX) | 0 0 0.0%
- Published:
08 Dec 2025 -
Author:
Jyoti Prakash, CFA | Arron Aatkar, PhD -
Pages:
2 -
Newron Pharmaceuticals has announced the launch of its Phase III ENIGMA-TRS 2 trial in the US, marking an important step for the registrational programme for lead candidate evenamide in treatment-resistant schizophrenia (TRS). ENIGMA-TRS 2 is a global, randomised, double-blind, placebo-controlled,